Table 1.
The performance of rEgAgB8/2, native antigen B, and commercial kit for the diagnosis of CE
| Type of serum | Number | Positive cases in commercial kit No. (%) |
Positive cases in native-AgB ELISA No. (%) |
Positive cases in rEgAgB8/2 ELISA No. (%) |
|---|---|---|---|---|
| CE patients | 30 | 29 (97) | 26 (87) | 27 (90) |
| Vitiligo | 3 | 0 | 0 | 0 |
| Behçet’s disease | 3 | 0 | 0 | 0 |
| Lupus | 3 | 0 | 0 | 0 |
| Giardiasis | 3 | 0 | 1 (33) | 0 |
| Hymenolepiasis | 3 | 0 | 0 | 0 |
| Toxocariasis | 3 | 1 (33) | 0 | 0 |
| Toxoplasmosis | 3 | 0 | 1 (33) | 1 (33) |
| Fascioliasis | 3 | 0 | 1 (33) | 1 (33) |
| FUO | 3 | 0 | 1 (33) | 0 |
| Malaria | 2 | 1 (50) | 0 | 0 |
| Cryptosporidiosis | 2 | 0 | 0 | 0 |
| Trichostrongyliasis | 1 | 0 | 0 | 0 |
| Healthy subjects | 30 | 1 (3.3) | 2 (6.7) | 2 (6.7) |